Enzalutamide in treatment of castrate-resistant prostate cancer

Abstract

Prostate cancer is one of the most common tumours in men. Castrate resistance of prostate cancer (CRPC) is a serious clinical problem.

Progress in the field of molecular biology enabled identification of the crucial role of signal transduction pathway dependent on the androgen receptor (AR) in CRPC. Enzalutamide is the first anti-androgen that interferes with mechanism of progression related to AR gene amplification and/or AR over-expression. The results of PREVAIL — phase 3 trial in population of men with metastatic CRPC not previously exposed to docetaxel were presented on ASCO GU 2014. These data prove significant advantage of enzalutamide use over placebo in regards to all study end-points.

Enzalutamide is the only drug that prolongs survival in men with CRPC not previously treated with docetaxel.